Excision repair cross‐complementation group 1 protein expression predicts survival in patients with high‐grade, non‐metastatic osteosarcoma treated with neoadjuvant chemotherapy. Issue 3 (5th March 2015)

• Record Type: Journal Article
• Authors: Hattinger, Claudia Maria; Michelacci, Francesca; Sella, Federica; Magagnoli, Giovanna; Benini, Stefania; Gambarotti, Marco; Palmerini, Emanuela; Picci, Piero; Serra, Massimo; Ferrari, Stefano
• Is Part Of: Histopathology. Volume 67:Issue 3(2015)
• Page Start: 338
• Page End: 347
• Publication Date: 2015-03-05
• Subjects: Histology, Pathological -- Periodicals; 611.018
• DOI: 10.1111/his.12653
• Languages: English
• ISSNs: 0309-0167

Abstract

<abstract abstract-type="main" id="his12653-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="his12653-sec-0001" sec-type="section"> <title>Aims</title> <p>To evaluate the clinical impact of excision repair cross‐complementation group 1 (ERCC1) expression in high‐grade osteosarcoma (OS).</p> </sec> <sec id="his12653-sec-0002" sec-type="section"> <title>Methods and results</title> <p>Immunohistochemistry was performed on biopsies from 99 OS patients enrolled in the ISG/OS‐Oss training set or ISG/SSG1 validation set neoadjuvant chemotherapy protocols, based on the use of cisplatin, adriamycin, methotrexate, and ifosfamide. In the training set, ERCC1 positivity was found in eight of 31 (26%) patients, and was significantly associated with worse event‐free survival (EFS) (<italic>P</italic> = 0.042) and overall survival (OVS) (<italic>P</italic> = 0.001). In the validation set, ERCC1 positivity was found in 22 of 68 (32%) patients, and its significant associations with poorer EFS (<italic>P</italic> = 0.028) and OVS (<italic>P</italic> = 0.022) were confirmed. Multivariate analyses performed on the whole patient series indicated that ERCC1 positivity was the only marker that was significantly associated with a higher risk of worse prognosis, in terms of both EFS and OVS (<italic>P</italic> = 0.013). Co‐evaluation of ERCC1 and ABCB1 expression showed that patients who were positive for both markers had a significantly worse prognosis.</p> </sec> <sec id="his12653-sec-0003" sec-type="section"> <title>Conclusions</title> <p>The ERCC1 level at diagnosis is predictive for the outcome of patients with non‐metastatic, high‐grade OS treated with neoadjuvant chemotherapy, and co‐evaluation with ABCB1 can identify high‐risk groups of OS patients who are refractory to standard regimens.</p> </sec> </abstract>